Get the Stockscreener App
270.14
1.63%
-4.47
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $270.14, with a volume of 1.26M.
It is down -1.63% in the last 24 hours and down -4.64% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$274.61
Open:
$273.15
24h Volume:
1.26M
Relative Volume:
1.32
Market Cap:
$39.55B
Revenue:
$5.15B
Net Income/Loss:
$1.40B
P/E Ratio:
28.41
EPS:
9.51
Net Cash Flow:
$1.65B
1W Performance:
-2.49%
1M Performance:
-4.64%
6M Performance:
+22.67%
1Y Performance:
+7.75%
1-Day Range:
$269.00
$273.56
1-Week Range:
$265.68
$281.32
52-Week Range:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
270.14 | 39.60B | 5.15B | 1.40B | 1.65B | 9.51 |
|
ISRG
Intuitive Surgical Inc
|
449.68 | 161.31B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
186.84 | 54.01B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
78.29 | 38.49B | 10.03B | 1.07B | 1.39B | 2.17 |
|
WST
West Pharmaceutical Services Inc
|
253.50 | 18.35B | 2.96B | 487.70M | 344.00M | 6.68 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Alliancebernstein L.P. Sells 110,645 Shares of ResMed Inc. $RMD - MarketBeat
PharVision Advisers LLC Makes New $219,000 Investment in ResMed Inc. $RMD - MarketBeat
Adage Capital Partners GP L.L.C. Reduces Stake in ResMed Inc. $RMD - MarketBeat
Goldman Sachs Group Inc. Grows Stock Position in ResMed Inc. $RMD - MarketBeat
Resmed : Stewardship Presentation - MarketScreener
ResMed (NYSE:RMD) Shares Down 4.7%Time to Sell? - MarketBeat
Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo Finance
Capital Impact Advisors LLC Acquires Shares of 38,139 ResMed Inc. $RMD - MarketBeat
Zurich Insurance Group Ltd FI Sells 329,029 Shares of ResMed Inc. $RMD - MarketBeat
Q2 Earnings Outperformers: ResMed (NYSE:RMD) And The Rest Of The Patient Monitoring Stocks - Yahoo Finance
Amundi Has $134.66 Million Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (RMD) Launches Global Sleep Institute at World Sleep Congress - Yahoo Finance
Petrus Trust Company LTA Purchases Shares of 1,144 ResMed Inc. $RMD - MarketBeat
United Services Automobile Association Acquires Shares of 3,441 ResMed Inc. $RMD - MarketBeat
Parkman Healthcare Partners LLC Takes $5.06 Million Position in ResMed Inc. $RMD - MarketBeat
Resmed Inc Reports Decrease in CDIs for August 2025 - MSN
ResMed, Insulet, Lantheus, Inspire Medical Systems, and Evolent Health Shares Plummet, What You Need To Know - Yahoo Finance
Royal Bank of Canada Boosts Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Stock Holdings Decreased by AQR Capital Management LLC - MarketBeat
ResMed Updates Dividend Exchange Rate for ASX CDI Holders - MSN
Is it Worth Retaining ResMed Stock in Your Portfolio Now? - MSN
ResMed CFO Acquires Shares Following Performance Milestone - MSN
Resmed Inc Announces Proposed Sale of Securities by Officer - MSN
1,648 Shares in ResMed Inc. $RMD Bought by Aprio Wealth Management LLC - MarketBeat
ResMed launches sleep research hub at Singapore’s World Sleep Congress - Mugglehead Magazine
Federation des caisses Desjardins du Quebec Buys 1,431 Shares of ResMed Inc. $RMD - MarketBeat
Will ResMed Inc. stock hit new highs in YEARWeekly Trade Summary & Daily Profit Maximizing Tips - beatles.ru
ResMed's (NYSE:RMD) Investors Will Be Pleased With Their Notable 66% Return Over the Last Five Years - 富途牛牛
Is ResMed Inc.’s growth already priced inJuly 2025 Fed Impact & Weekly Market Pulse Alerts - classian.co.kr
ResMed (NYSE:RMD) Upgraded by CLSA to Outperform Rating - MarketBeat
Can momentum traders help lift ResMed Inc.2025 Risk Factors & Long-Term Growth Portfolio Plans - Newser
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease - simplywall.st
What ResMed (RMD)'s VirtuOx Acquisition and Q4 Growth Reveal About Its Evolving Strategy - simplywall.st
Regression analysis insights on ResMed Inc. performanceJuly 2025 PostEarnings & Safe Entry Zone Tips - Newser
Lansforsakringar Fondforvaltning AB publ Increases Stock Position in ResMed Inc. $RMD - MarketBeat
Using AI based signals to follow ResMed Inc.2025 Momentum Check & Reliable Entry Point Trade Alerts - Newser
BNP Paribas Financial Markets Increases Stock Position in ResMed Inc. $RMD - MarketBeat
Does ResMed Inc. stock have upside surprise potential2025 Trading Recap & Fast Entry Momentum Trade Alerts - خودرو بانک
Long term hold vs stop loss in ResMed Inc.Dividend Hike & AI Enhanced Trade Execution Alerts - Newser
Best data tools to analyze ResMed Inc. stock2025 Historical Comparison & Precise Swing Trade Entry Alerts - Newser
Advanced analytics toolkit walkthrough for ResMed Inc.July 2025 Levels & Reliable Breakout Forecasts - Newser
Stock Analysis | ResMed OutlookBalancing Technical Neutrality and Strong Fundamentals - AInvest
Does ResMed Inc. have a competitive edge2025 Risk Factors & Fast Entry Momentum Trade Alerts - خودرو بانک
Is ResMed Inc. trading at a discountJuly 2025 WrapUp & Risk Adjusted Buy/Sell Alerts - خودرو بانک
Vident Advisory LLC Raises Stock Position in ResMed Inc. $RMD - MarketBeat
Predicting ResMed Inc. trend using moving averagesWeekly Gains Summary & Fast Exit and Entry Trade Guides - Newser
ResMed Inc.’s volatility index tracking explainedPortfolio Performance Report & Real-Time Stock Movement Alerts - Newser
Is ResMed Inc. stock reversal real or fake2025 Biggest Moves & Low Risk High Win Rate Picks - Newser
Insider Sell: What’s the analyst consensus on ResMed Inc.Portfolio Gains Report & Safe Investment Capital Preservation Plans - خودرو بانک
Day 7 of Loss Streak for ResMed Stock with -8.3% Return (vs. 18% YTD) [9/3/2025] - Trefis
Should you wait for a breakout in ResMed Inc.July 2025 EndofMonth & Weekly Top Gainers Alerts - Newser
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):